Novo Nordisk CEO encouraged by Saxenda's role in obesity business growth
The growth of Novo Nordisk's obesity business cannot all be ascribed to the new weight loss drug Wegovy, says Novo Nordisk CEO Lars Fruergaard Jørgensen. Its predecessor, Saxenda, is also doing well, reports the CEO.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Although Novo Nordisk still doesn't want to report the individual sales figures for its two obesity treatments – Saxenda and its heir, Wegovy – the positive progress in the business area is there for anyone to see in Wednesday's quarterly report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
